Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Joseph C. Torkildson

Pediatric Hematology Oncology

1432 S Dobson Rd Ste 107,

Mesa, AZ

Offers Telehealth

Advanced in Embryonal Tumor with Multilayered Rosettes

1432 S Dobson Rd Ste 107,

Mesa, AZ

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Torkildson is a Pediatric Hematologist Oncology provider in Mesa, Arizona. Dr. Torkildson is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Ganglioglioma, Medulloblastoma, Glioma, Reticulohistiocytoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 34 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 17 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in AZ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Blue Cross Blue Shield

Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana

HMO
INDEMNITY
POS
PPO

Medicaid

OTHER MEDICAID
STATE MEDICAID

MercyCare

Oscar

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 4 Less Insurance Carriers -

Locations

1432 S Dobson Rd Ste 107, Mesa, AZ 85202

Call: 480-412-4100

Additional Areas of Focus

Dr. Torkildson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Radiation

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Enrollment Status: Completed

Publish Date: September 09, 2025

Intervention Type: Drug

Study Drug: Everolimus

Study Phase: Phase 2

StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2025

Intervention Type: Other, Behavioral, Device

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Tyrosine Kinase Inhibitor

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

Enrollment Status: Completed

Publish Date: August 03, 2025

Intervention Type: Drug

Study Drug: Vemurafenib

Study Phase: Early Phase 1

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Enrollment Status: Completed

Publish Date: November 19, 2024

Intervention Type: Drug, Radiation

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years

Enrollment Status: Active_not_recruiting

Publish Date: October 26, 2024

Intervention Type: Drug, Radiation, Biological, Other

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine

Study Phase: Phase 3

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 22, 2024

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide

Study Phase: Phase 2

A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

Enrollment Status: Completed

Publish Date: July 16, 2018

Intervention Type: Other

View 32 Less Clinical Trials

11 Total Publications

Utilization of Thiopurine Metabolites and Allopurinol in Pediatric Acute Lymphoblastic Leukemia: Consideration for an Algorithmic Approach.

Journal: Journal of pediatric hematology/oncology

Published: November 04, 2020

View All 11 Publications

Similar Doctors

Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Santosh S. Hanmod

Pediatric Hematology Oncology

Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Santosh S. Hanmod

Pediatric Hematology Oncology

1432 S Dobson Rd Ste 107,

Mesa, AZ

(0.1 miles away)

480-412-4100

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Santosh Hanmod is a Pediatric Hematologist Oncology provider in Mesa, Arizona. Dr. Hanmod is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Hepatoblastoma, Histiocytosis, Reticulohistiocytoma, Neuroblastoma, and Bone Marrow Aspiration.

Experienced in Embryonal Tumor with Multilayered Rosettes

Dr. Jessica L. Boklan

Pediatric Hematology Oncology

Experienced in Embryonal Tumor with Multilayered Rosettes

Dr. Jessica L. Boklan

Pediatric Hematology Oncology

1919 E Thomas Rd,

Phoenix, AZ

(11.7 miles away)

602-546-0920

Languages Spoken:

English

See accepted insurances

Jessica Boklan is a Pediatric Hematologist Oncology provider in Phoenix, Arizona. Dr. Boklan is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Leukemia, Acute Lymphoblastic Leukemia (ALL), Aplastic Anemia, Infantile Neutropenia, and Bone Marrow Aspiration.

Experienced in Embryonal Tumor with Multilayered Rosettes

Dr. Mario Otto

Pediatric Hematology Oncology

Experienced in Embryonal Tumor with Multilayered Rosettes

Dr. Mario Otto

Pediatric Hematology Oncology

1919 E Thomas Rd,

Phoenix, AZ

(11.7 miles away)

602-933-0920

Languages Spoken:

English

See accepted insurances

Mario Otto is a Pediatric Hematologist Oncology provider in Phoenix, Arizona. Dr. Otto is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Rhabdomyosarcoma, Alpha Thalassemia, and Bone Marrow Transplant.

VIEW MORE EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Torkildson's expertise for a condition

ConditionClose